Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Price for Pfizer COVID Vaccine Includes Company Distribution Efforts Directed By DOD, CDC

Executive Summary

Pfizer is responsible for distribution work as part of its $1.95bn agreement with the US government for its COVID-19 vaccine. The CDC and Defense Department will lead a joint vaccination effort, senior adminsitration officals said, raising concerns of public health experts who say DOD support will be useful for the unprecented vaccination campaign, but public health leadership will be critical for public buy-in.

You may also be interested in...

COVID Vaccine Distribution: Pfizer Plans ‘Dry Run’ With Four States

Unflustered by cold-chain complications, Pfizer aims to use it experience in shipping vaccine to its trial sites to show states of different sizes, diversity of populations and immunization infrastructures how best to distribute its product.

Obama-Era Contract, Past Track Record Lands McKesson COVID-19 Vaccine Distribution Deal

The previous administration’s forethought may have given the Trump team a leg up in vaccine distribution. McKesson’s experience as a central distributor for the Vaccines for Children’s program, H1N1 and its role in seasonal flu vaccine distribution should make it well positioned to handle the COVID-19 effort in the US, experts said. 

AstraZeneca, Janssen, Novavax Likely To Be Next ‘Warp Speed’ Vaccines In Phase III

While AstraZeneca’s adenovirus candidate is expected to use Operation Warp Speed’s platform, its start date remains cloaked; the Janssen and Novavax candidates are expected to enter Phase III in September and October, respectively.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts